| Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non … KK Jørgensen, IC Olsen, GL Goll, M Lorentzen, N Bolstad, ... The Lancet 389 (10086), 2304-2316, 2017 | 925 | 2017 |
| High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year … SW Syversen, PI Gaarder, GL Goll, S Ødegård, EA Haavardsholm, ... Annals of the rheumatic diseases 67 (2), 212-217, 2008 | 382 | 2008 |
| Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study SW Syversen, GL Goll, D van der Heijde, R Landewé, BA Lie, S Ødegård, ... Annals of the rheumatic diseases 69 (2), 345-351, 2010 | 208 | 2010 |
| Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study I Jyssum, H Kared, TT Tran, AT Tveter, SA Provan, J Sexton, ... The Lancet Rheumatology 4 (3), e177-e187, 2022 | 144 | 2022 |
| Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial GL Goll, KK Jørgensen, J Sexton, IC Olsen, N Bolstad, EA Haavardsholm, ... Journal of internal medicine 285 (6), 653-669, 2019 | 119 | 2019 |
| Effect of therapeutic drug monitoring vs standard therapy during infliximab induction on disease remission in patients with chronic immune-mediated inflammatory diseases: a … SW Syversen, GL Goll, KK Jørgensen, Ø Sandanger, J Sexton, IC Olsen, ... Jama 325 (17), 1744-1754, 2021 | 118 | 2021 |
| Effect of therapeutic drug monitoring vs standard therapy during maintenance infliximab therapy on disease control in patients with immune-mediated inflammatory diseases: a … SW Syversen, KK Jørgensen, GL Goll, MK Brun, Ø Sandanger, ... Jama 326 (23), 2375-2384, 2021 | 112 | 2021 |
| The ACPA isotype profile reflects long-term radiographic progression in rheumatoid arthritis D van der Woude, SW Syversen, EIH van der Voort, KN Verpoort, GL Goll, ... Annals of the rheumatic diseases 69 (6), 1110-1116, 2010 | 107 | 2010 |
| Cartilage and bone biomarkers in rheumatoid arthritis: prediction of 10-year radiographic progression SW Syversen, GL Goll, D van der HEIJDE, R Landewe, PI Gaarder, ... The Journal of rheumatology 36 (2), 266-272, 2009 | 90 | 2009 |
| Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia S Holm, H Kared, AE Michelsen, XY Kong, TB Dahl, NH Schultz, ... European Heart Journal 42 (39), 4064-4072, 2021 | 56 | 2021 |
| Biomarkers in early rheumatoid arthritis: longitudinal associations with inflammation and joint destruction measured by magnetic resonance imaging and conventional radiographs SW Syversen, EA Haavardsholm, P Bøyesen, GL Goll, C Okkenhaug, ... Annals of the rheumatic diseases 69 (5), 845-850, 2010 | 56 | 2010 |
| Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons T Uhlig, GL Goll Rheumatology 56 (suppl_4), iv49-iv62, 2017 | 55 | 2017 |
| A high serum level of eotaxin (CCL 11) is associated with less radiographic progression in early rheumatoid arthritis patients SW Syversen, GL Goll, EA Haavardsholm, P Bøyesen, T Lea, TK Kvien Arthritis research & therapy 10, 1-4, 2008 | 52 | 2008 |
| EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases CLM Krieckaert, A van Tubergen, JE Gehin, B Hernández-Breijo, ... Annals of the rheumatic diseases 82 (1), 65-73, 2023 | 45 | 2023 |
| Immunogenicity and Safety of Standard and Third‐Dose SARS–CoV‐2 Vaccination in Patients Receiving Immunosuppressive Therapy SW Syversen, I Jyssum, AT Tveter, TT Tran, J Sexton, SA Provan, ... Arthritis & Rheumatology 74 (8), 1321-1332, 2022 | 45 | 2022 |
| Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV … SW Syversen, GL Goll, KK Jørgensen, IC Olsen, Ø Sandanger, JE Gehin, ... Trials 21, 1-14, 2020 | 36 | 2020 |
| Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study JE Gehin, GL Goll, DJ Warren, SW Syversen, J Sexton, EK Strand, ... Arthritis Research & Therapy 21, 1-10, 2019 | 33 | 2019 |
| Metabolic profiling of synovial tissue shows altered glucose and choline metabolism in rheumatoid arthritis samples R Volchenkov, M Dung Cao, KB Elgstøen, GL Goll, K Eikvar, O Bjørneboe, ... Scandinavian Journal of Rheumatology 46 (2), 160-161, 2017 | 31 | 2017 |
| Biosimilar infliximab (CT-P13) is not inferior to originator infliximab: results from a 52-week randomized switch trial in Norway GL Goll, IC Olsen, KK Jorgensen, M Lorentzen, N Bolstad, ... Arthritis & rheumatology 68, 2016 | 28 | 2016 |
| Interleukin‐15 induces interleukin‐17 production by synovial T cell lines from patients with rheumatoid arthritis EH Halvorsen, E Strønen, HB Hammer, GL Goll, LM Sollid, Ø Molberg Scandinavian journal of immunology 73 (3), 243-249, 2011 | 27 | 2011 |
